

March 8, 2019

Harold Shlevin  
Chief Executive Officer  
Galectin Therapeutics Inc.  
4960 Peachtree Industrial Blvd., Suite 240  
Norcross, GA 30071

Re: Galectin Therapeutics Inc.  
Registration Statement on Form S-3  
Filed March 6, 2019  
File No. 333-230085

Dear Dr. Shlevin:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Dorrie Yale at 202-551-8776 with any questions.

Sincerely,

Division of

Office of

Corporation Finance  
Healthcare & Insurance  
cc: Robert E. Tritt